154 related articles for article (PubMed ID: 26434815)
1. Survivin as a Potential Target for Cancer Therapy.
Soleimanpour E; Babaei E
Asian Pac J Cancer Prev; 2015; 16(15):6187-91. PubMed ID: 26434815
[TBL] [Abstract][Full Text] [Related]
2. Survivin as a prognostic/predictive marker and molecular target in cancer therapy.
Rödel F; Sprenger T; Kaina B; Liersch T; Rödel C; Fulda S; Hehlgans S
Curr Med Chem; 2012; 19(22):3679-88. PubMed ID: 22680927
[TBL] [Abstract][Full Text] [Related]
3. Survivin as a preferential target for cancer therapy.
Mobahat M; Narendran A; Riabowol K
Int J Mol Sci; 2014 Feb; 15(2):2494-516. PubMed ID: 24531137
[TBL] [Abstract][Full Text] [Related]
4. Survivin in survival of hepatocellular carcinoma.
Su C
Cancer Lett; 2016 Sep; 379(2):184-90. PubMed ID: 26118774
[TBL] [Abstract][Full Text] [Related]
5. Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers.
Singh N; Krishnakumar S; Kanwar RK; Cheung CH; Kanwar JR
Drug Discov Today; 2015 May; 20(5):578-87. PubMed ID: 25433305
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticle-mediated inhibition of survivin to overcome drug resistance in cancer therapy.
Wang S; Xu Y; Chan HF; Kim HW; Wang Y; Leong KW; Chen M
J Control Release; 2016 Oct; 240():454-464. PubMed ID: 27091696
[TBL] [Abstract][Full Text] [Related]
7. Monitoring survivin expression in cancer: implications for prognosis and therapy.
Santa Cruz Guindalini R; Mathias Machado MC; Garicochea B
Mol Diagn Ther; 2013 Dec; 17(6):331-42. PubMed ID: 23912862
[TBL] [Abstract][Full Text] [Related]
8. Treat cancers by targeting survivin: just a dream or future reality?
Coumar MS; Tsai FY; Kanwar JR; Sarvagalla S; Cheung CH
Cancer Treat Rev; 2013 Nov; 39(7):802-11. PubMed ID: 23453862
[TBL] [Abstract][Full Text] [Related]
9. Survivin: A molecular biomarker in cancer.
Jaiswal PK; Goel A; Mittal RD
Indian J Med Res; 2015 Apr; 141(4):389-97. PubMed ID: 26112839
[TBL] [Abstract][Full Text] [Related]
10. Survivin--prognostic tumor biomarker in human neoplasms--review.
Waligórska-Stachura J; Jankowska A; Waśko R; Liebert W; Biczysko M; Czarnywojtek A; Baszko-Błaszyk D; Shimek V; Ruchała M
Ginekol Pol; 2012 Jul; 83(7):537-40. PubMed ID: 22880480
[TBL] [Abstract][Full Text] [Related]
11. An Old Flame Never Dies: Survivin in Cancer and Cellular Senescence.
Unruhe B; Schröder E; Wünsch D; Knauer SK
Gerontology; 2016; 62(2):173-81. PubMed ID: 26159786
[TBL] [Abstract][Full Text] [Related]
12. Withanone as an inhibitor of survivin: a potential drug candidate for cancer therapy.
Wadegaonkar VP; Wadegaonkar PA
J Biotechnol; 2013 Oct; 168(2):229-33. PubMed ID: 23994265
[TBL] [Abstract][Full Text] [Related]
13. Targeted Microbubbles for Ultrasound Mediated Short Hairpin RNA Plasmid Transfection to Inhibit Survivin Gene Expression and Induce Apoptosis of Ovarian Cancer A2780/DDP Cells.
Zhang Y; Chang S; Sun J; Zhu S; Pu C; Li Y; Zhu Y; Wang Z; Xu RX
Mol Pharm; 2015 Sep; 12(9):3137-45. PubMed ID: 26212628
[TBL] [Abstract][Full Text] [Related]
14. Growth inhibition and chemo-radiosensitization of head and neck squamous cell carcinoma (HNSCC) by survivin-siRNA lentivirus.
Khan Z; Khan AA; Prasad GB; Khan N; Tiwari RP; Bisen PS
Radiother Oncol; 2016 Feb; 118(2):359-68. PubMed ID: 26747757
[TBL] [Abstract][Full Text] [Related]
15. Overview of role of survivin in cancer: expression, regulation, functions, and its potential as a therapeutic target.
Fang XL; Cao XP; Xiao J; Hu Y; Chen M; Raza HK; Wang HY; He X; Gu JF; Zhang KJ
J Drug Target; 2024 Dec; 32(3):223-240. PubMed ID: 38252514
[TBL] [Abstract][Full Text] [Related]
16. Survivin Modulators: An Updated Patent Review (2011-2015).
Roy K; Singh N; Kanwar RK; Kanwar JR
Recent Pat Anticancer Drug Discov; 2016; 11(2):152-69. PubMed ID: 26924735
[TBL] [Abstract][Full Text] [Related]
17. Survivin-Based Treatment Strategies for Squamous Cell Carcinoma.
Santarelli A; Mascitti M; Lo Russo L; Sartini D; Troiano G; Emanuelli M; Lo Muzio L
Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29587347
[TBL] [Abstract][Full Text] [Related]
18. Survivin: an inhibitor of apoptosis in pediatric cancer.
Fangusaro JR; Caldas H; Jiang Y; Altura RA
Pediatr Blood Cancer; 2006 Jul; 47(1):4-13. PubMed ID: 16534789
[TBL] [Abstract][Full Text] [Related]
19. Clinico-pathologic relevance of Survivin splice variant expression in cancer.
Necochea-Campion Rd; Chen CS; Mirshahidi S; Howard FD; Wall NR
Cancer Lett; 2013 Oct; 339(2):167-74. PubMed ID: 23791888
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional and post-transcriptional controls of survivin in cancer cells: novel approaches for cancer treatment.
Zhang M; Yang J; Li F
J Exp Clin Cancer Res; 2006 Sep; 25(3):391-402. PubMed ID: 17167980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
